KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Ratios

Takeda Pharmaceutical (TAK) Other Accumulated Expenses (2025 - 2026)

Takeda Pharmaceutical has reported Other Accumulated Expenses over the past 2 years, most recently at $3.8 billion for Q1 2026.

For Q1 2026, Other Accumulated Expenses fell 3.72% year-over-year to $3.8 billion; the TTM value through Mar 2026 reached $3.8 billion, down 3.72%, while the annual FY2026 figure was $3.9 billion, 0.15% changed from the prior year.
Other Accumulated Expenses was $3.8 billion for Q1 2026 at Takeda Pharmaceutical, down from $3.9 billion in the prior quarter.
Across five years, Other Accumulated Expenses topped out at $3.9 billion in Q1 2025 and bottomed at $3.8 billion in Q1 2026.